Finland· FI-REL-REL39445
Bexsero
A meningokokkus b, multikomponenten-impfstoff product containing neisseria meningitidis group b nhba fusion protein, recombinant + neisseria meningitidis group b nada protein, recombinant + neisseria meningitidis group b fhbp fusion protein, recombinant + neisseria meningitidis group b (nz98/254) omv, registered in Finland by Glaxosmithkline Vaccines S.r.l.. The same ATC class is registered in 11 of our 19 countries.
Checked against Fimea (Finland) on
Informational only — not a medical device.
Where it is registered
Meningokokkus b, multikomponenten-impfstoff is registered in 11 of 19 countries.
Countries holding a registration under ATC J07AH09 (meningokokkus b, multikomponenten-impfstoff), each read from that country’s own register.
- This record: Finland, from Fimea (Finland)
- 7 of them publish a price we can compare per daily dose
Meningokokkus b, multikomponenten-impfstoff · ATC J07AH09
11 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
The record
At a glance
Fimea (Finland)- Active substance
- Neisseria meningitidis group B NHBA fusion protein, recombinant + Neisseria meningitidis group B NadA protein, recombinant + Neisseria meningitidis group B fHBP fusion protein, recombinant + Neisseria meningitidis group B (NZ98/254) OMV
- Manufacturer
- Glaxosmithkline Vaccines S.r.l.
- Country
- Finland (FI)
- ATC code
- J07AH09
- ATC class
- Meningokokkus B, Multikomponenten-Impfstoff
- Reimbursed
- Not published by this register
- Source register
- Fimea (Finland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same class
Other records under J07AH09
Meningokokkus b, multikomponenten-impfstoff, as other registers publish it.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/a227d9ad-d4dd-4e59-92ec-0b1828941cc3 GET /v1/drugs/a227d9ad-d4dd-4e59-92ec-0b1828941cc3?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"ddd": null,
"form": "injektioneste, suspensio, esitäytetty ruisku",
"route": "Lihakseen",
"ddd_unit": null,
"strength": null,
"atc_label": "meningokokki B, monikomponenttinen rokote",
"ma_number": null,
"auth_status": "Myyntilupa myönnetty",
"eu_ma_number": "EU/1/12/812/001-004",
"fimea_rel_id": "REL39445",
"authorised_at": "2013-01-14"
}See everything about meningokokkus b, multikomponenten-impfstoff.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.